Resolve Therapeutics
Manufacturing · Florida, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
721 1st Ave N, Saint Petersburg, Florida...Phone Number
(425) 576-4100Website
www.resolvetherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Resolve Therapeutics
Resolve Therapeutics, LLC focuses on addressing chronic and acute inflammation through innovative treatments. The company has developed two nuclease Fc fusion protein drugs, RSLV-132 and RSLV-145, which digest harmful RNA and DNA, thereby reducing inflammation at its source. Their clinical studies show positive results in treating conditions such as systemic lupus erythematosus, Sjogren's syndrome, and long COVID. Resolve Therapeutics aims to explore additional clinical indications where nucleic acids play a significant role in disease progression.Explore more
Resolve Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Resolve Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Resolve Therapeutics recently announced quarterly report
Check if Resolve Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Resolve Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Resolve Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Resolve Therapeutics
Resolve Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Resolve Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Resolve Therapeutics launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Resolve Therapeutics
Compare insights from companies similar to Resolve Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Resolve Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Resolve Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Resolve Therapeutics.
Resolve Therapeutics financials insights
Gather financial insights about Resolve Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Series A
$2M
2012
Series B
$5.8M
Resolve Therapeutics Tech Stack
A closer look at the technologies used by Resolve Therapeutics
See more technologies
Resolve Therapeutics News & Media
Resolve Therapeutics and Duke Medical School Initiate Observational Study of Cell-free RNA in Polytrauma Patients
MIAMI--(BUSINESS WIRE)--Resolve Therapeutics, a leader in the emerging field of cell-free nucleic acid therapeutics, today announced a collaboration with the Department of Surgery, Duke University School of Medicine to analyze the role of cell-free RNA (cfRNA) in polytrauma www.resolvetherapeutics.com. A significant number of trauma patients admitted to the hospital each year suffer from polytrauma, with multiple, life-threatening injuries requiring immediate surgical intervention. Many of thesResolve Therapeutics Publishes Results of RSLV-132 Phase 2 Long COVID Study
MIAMI, May 13, 2024 /PRNewswire/ -- Resolve Therapeutics, a mid-stage clinical development company pioneering transformative therapies for autoimmune and post-viral illnesses, today announced the publication of its phase 2 long COVID results in Clinical Infectious Diseases. The...Resolve Therapeutics Announces Publication of Lupus Clinical Trial Results
MIAMI, Feb. 12, 2024 /PRNewswire/ -- Resolve Therapeutics, a mid-stage clinical development biotechnology company pioneering first-in-class therapies for autoimmune diseases, today announced the publication of results from its phase 2a clinical trial of RSLV-132 in patients with Systemic...Resolve Therapeutics Completes Enrollment of Phase 2 Long Covid Clinical Trial
ST. PETERSBURG, Fla., Nov. 9, 2022 /PRNewswire/ -- Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced that its phase 2 clinical trial of RSLV-132 in patients with long covid has been fully enrolled (NCT04944121)....
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Resolve Therapeutics
Sign Up For FreeTo access detailed company insights
Resolve Therapeutics, LLC focuses on addressing chronic and acute inflammation through innovative treatments. The company has developed two nuclease Fc fusion protein drugs, RSLV-132 and RSLV-145, which digest harmful RNA and DNA, thereby reducing inflammation at its source. Their clinical studies show positive results in treating conditions such a... Read More
